Cambridge biotechs head for the (cheaper) 'burbs

Shire Human Genetic Therapies and a string of smaller drug developers have decided to pull up stakes from Cambridge and head for the suburbs. The report says the exodus is being triggered by a desire to find less expensive digs. The city has contributed to creating one of the biggest biotech clusters in the world, but developers have been balking at the high rents they face in town. For growing companies, the desire to get everyone under one roof can be a particular challenge.

- read the article in the Boston Globe

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.